Table of Contents

company-logo

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

Acrivon Therapeutics Dividend Announcement

• Acrivon Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Acrivon Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Acrivon Therapeutics Dividend History

Acrivon Therapeutics Dividend Yield

Acrivon Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Acrivon Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Acrivon Therapeutics Financial Ratios

P/E ratio-4.31
PEG ratio1.95
P/B ratio1.38
ROE-47.31%
Payout ratio0.00%
Current ratio16.16
Quick ratio16.16
Cash Ratio4.08

Acrivon Therapeutics Dividend FAQ

Does Acrivon Therapeutics stock pay dividends?
Acrivon Therapeutics does not currently pay dividends to its shareholders.
Has Acrivon Therapeutics ever paid a dividend?
No, Acrivon Therapeutics has no a history of paying dividends to its shareholders. Acrivon Therapeutics is not known for its dividend payments.
Why doesn't Acrivon Therapeutics pay dividends?
There are several potential reasons why Acrivon Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Acrivon Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Acrivon Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Acrivon Therapeutics a dividend aristocrat?
Acrivon Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Acrivon Therapeutics a dividend king?
Acrivon Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Acrivon Therapeutics a dividend stock?
No, Acrivon Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Acrivon Therapeutics stocks?
To buy Acrivon Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Acrivon Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.